Claims
- 1. A compound of the formula: or a physiologically acceptable salt thereof.
- 2. The compound according to claim 1, which is (R,S)-1-(4,4,4-trifluoro-1-butylsulphonyl)oxy-3-(2-hydroxymethylindanyl-4-oxy)-benzene, or a physiologically acceptable salt thereof.
- 3. The compound according to claim 1, which is (R)-1-(4,4,4-trifluoro-1-butylsulphonyl)oxy-3-(2-hydroxymethylindanyl-4-oxy)-benzene, or a physiologically acceptable salt thereof.
- 4. The compound according to claim 1, which is (S)-1-(4,4,4-trifluoro-1-butylsulphonyl)oxy-3-(2-hydroxymethylindanyl-4-oxy)-benzene, or a physiologically acceptable salt thereof.
- 5. A pharmaceutical composition comprising a compound or physiologically acceptable salt thereof according to any one of claims 1-4 and a physiologically acceptable carrier.
- 6. A method for preventing and/or treating a neurodegenerative disorder, said method comprising, administering to an individual an effective amount therefor of a compound or physiologically acceptable salt thereof according to any one of claims 1-4.
- 7. A method for preventing or treating cerebral ischaemia and craniocerebral trauma, said method comprising administering to an individual an effective amount therefor of a compound or physiologically acceptable salt thereof according to any one of claims 1-4.
- 8. A method for treating a condition selected from states of pain, nemesis, nausea, glaucoma, asthma, anorexia, convulsions, rheumatism, sedation and mobility disorders, said method comprising administering to an individual an effective amount therefor of a compound or physiologically acceptable salt thereof according to any one of claims 1-4.
- 9. A method for treating a condition selected from bacterial infections, viral infections, autoimmune diseases, and inflammatory or autoimmunologically related diseases of the joints of the bone and muscle apparatus, of the interred and external organs, of the central nervous system, of the sense organs and of the haematogenic system, said method comprising administering to an individual an effective amount therefor of a compound or physiologically acceptable salt thereof according to any one of claims 1-4.
Priority Claims (2)
Number |
Date |
Country |
Kind |
197 06 902 |
Feb 1997 |
DE |
|
197 40 785 |
Sep 1997 |
DE |
|
Parent Case Info
This application is a 371 of PCT/EP98/00716, which was filed on Feb. 10, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP98/00716 |
|
WO |
00 |
11/15/1999 |
11/15/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO98/37061 |
8/27/1998 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4931457 |
Effland |
Jun 1990 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
2136828 |
Sep 1987 |
DE |
261539 |
Sep 1987 |
EP |
Non-Patent Literature Citations (2)
Entry |
Shein et al, Chemical Abstracts, vol. 78:135,804, May 1973.* |
International Search Report for PCT/EP98/00716, May 1999. |